FAIRFIELD, N.J., Jan. 28 /PRNewswire/ -- Arno Therapeutics, Inc., a
privately held drug development company, announced that it has entered into
worldwide, exclusive license agreements with The Ohio State University
("OSU") for the rights to commercially develop novel, orally available,
targeted therapies for cancer.
Pursuant to the license agreements, Arno acquired the rights to several
small molecules for the treatment of cancer, including OSU-03012 (NSC
D728209) and OSU-HDAC42 (NSC D736012). Both agents were developed by
Ching-Shih Chen, Ph.D., a professor of pharmacy and internal medicine at
Ohio State and a researcher in OSU's Comprehensive Cancer Center.
OSU-03012 is a PDK-1 inhibitor that targets the Akt pathway, and also
possesses activity in alternate pathways to target apoptosis and
angiogenesis. Preclinical data have demonstrated activity in multiple tumor
types and synergistic activity with other agents including Avastin(R),
Herceptin(R), Tarceva(R), Gleevec(R) and tamoxifen.
OSU-HDAC42 is a broad spectrum histone-deacetylase inhibitor which
possesses additional mechanisms as well. In preclinical studies OSU-HDAC42
has demonstrated greater potency and a competitive profile in solid and
liquid tumors when compared with vorinostat (SAHA), the leading marketed
compound in the class.
"We are extremely pleased to be developing these two exciting and novel
molecules for the treatment of cancer patients," said Scott Z. Fields,
M.D., President and CMO of Arno. "We look forward to moving these molecules
into the clinic and to hopefully bringing their benefits to patients who
need them as soon as possible."
"The out-licensing of these two very important molecularly targeted
oncology compounds to Arno Therapeutics is a significant milestone for Ohio
State," said Dr. Michael Caligiuri, director of the Ohio State University
Comprehensive Cancer Center and CEO of The James Cancer Hospital and Solove
Research Institute. "These are the first two molecules for cancer treatment
created entirely at OSU that will be brought into the cancer clinic."
Pursuant to the terms of the license agreement, Arno will pay
development based milestones and royalties based on sales of the licensed
Arno plans to initiate Phase I clinical trials for both OSU-03012 and
OSU- HDAC42 in 2009.
About Arno Therapeutics, Inc.
Arno Therapeutics is a biopharmaceutical company that develops and
commercializes innovative products for the treatment of cancer patients.
Arno is initially focusing its efforts on developing its lead compound,
DB-67, a novel anti-cancer agent. DB-67 is a third generation campthothecin
analogue that has demonstrated high potency and significantly improved
pharmacokinetic properties as demonstrated by greater stability of the
active lactone form in pre-clinical studies as compared with
second-generation products. Arno is currently enrolling patients in a Phase
I clinical trial. A key component of the Company's strategy is to acquire
global rights to additional product candidates for the treatment of cancer
while continuing to use its technology to develop and commercialize new
products and line extensions. For more information on Arno please visit
Scott Z. Fields, M.D.
President and CMO
Arno Therapeutics, Inc.
This news release contains forward-looking statements that involve
risks and uncertainties that could cause our actual results and experiences
to differ materially from anticipated results and expectations expressed in
such forward-looking statement. These statements are based on our current
beliefs and expectations as to such future outcomes. Drug discovery and
development involve a high degree of risk. Factors that might cause such a
material difference include, among others, uncertainties related to the
ability to attract and retain partners for our technologies, the
identification of lead compounds, the successful preclinical development
thereof, the completion of clinical trials, the FDA review process and
other governmental regulation, our pharmaceutical collaborator's ability to
successfully develop and commercialize drug candidates, competition from
other pharmaceutical companies, and product pricing and third party
reimbursement. We undertake no obligation to update any forward-looking
statement contained in this press release, except as required by law.
SOURCE Arno Therapeutics, Inc.